Macrophage colony-stimulating factor (M-CSF) influences the proliferation and survival of mononuclear phagocytes through the receptor CSF-1R. The adaptor protein DAP12 is critical for the function of mononuclear phagocytes. DAP12-mutant mice and humans have defects in osteoclasts and microglia, as well as brain and bone abnormalities. Here we show DAP12 deficiency impaired the M-CSF-induced proliferation and survival of macrophages in vitro. DAP12-deficient mice had fewer microglia in defined central nervous system areas, and DAP12-deficient progenitors regenerated myeloid cells inefficiently after bone marrow transplantation. Signaling by M-CSF through CSF-1R induced the stabilization and nuclear translocation of b-catenin, which activated genes involved in the cell cycle. DAP12 was essential for phosphorylation and nuclear accumulation of b-catenin. Our results provide a mechanistic explanation for the many defects of DAP12-deficient mononuclear phagocytes.
Macrophage colony-stimulating factor (M-CSF (A001489); also known as colony-stimulating factor 1 (CSF-1), is the main regulator of the proliferation, survival and differentiation of mononuclear phagocytes, which include monocytes, macrophages and bone-resorbing osteoclasts and their precursors [1] [2] [3] . M-CSF acts through the receptor CSF-1R (A000674), a tyrosine kinase encoded by the proto-oncogene Csf1r 4 that is expressed exclusively on mononuclear phagocytes. Binding of M-CSF to CSF-1R results in the formation of receptor dimers, the autophosphorylation of several tyrosine residues located in the cytoplasmic domain and the phosphorylation of many other proteins, including the phosphatase SHP-1 and the kinases Src, PLC-g, PI(3)K, Akt and Erk [5] [6] [7] [8] . The M-CSF-CSF-1R complex is subsequently internalized and degraded in lysosomes. Signaling through CSF-1R is required for entry of cells into S phase 9, 10 and for cell survival 11 . The biological importance of the M-CSF-CSF-1R axis is demonstrated by osteopetrotic (op/op) mice, which lack a functional gene encoding M-CSF (Csf1) 12 . These mice develop osteopetrosis due to impaired osteoclast formation, as well as deficits in blood monocytes and tissue macrophages. In vitro, M-CSF-CSF-1R signaling drives the proliferation and differentiation of precursor cells into macrophages or osteoclasts and is required for the survival of these cells. However, mononuclear phagocytes are not uniformly dependent on M-CSF 13 ; although some subpopulations continuously require M-CSF, others, such as microglia, depend on M-CSF only in specific areas of the central nervous system (CNS) [14] [15] [16] . DAP12 (A000750) is an adaptor protein associated with several myeloid and lymphocyte receptors; these receptors require DAP12 for cell surface expression and signaling 17 . DAP12 consists of a short extracellular and transmembrane region followed by a cytoplasmic domain that contains an immunoreceptor tyrosine-based activation motif (ITAM). After engagement of the associated receptor, the DAP12 ITAM is phosphorylated and acts as a docking site for the protein tyrosine kinases Syk and Zap70, which recruit and activate multiple 'downstream' adaptors and signaling enzymes that induce cell activation. The crucial function of DAP12 and DAP12-associated receptors in the function of mononuclear phagocytes is manifested in the human disorder of Nasu-Hakola disease (NHD), which is caused by a recessive mutation in the gene encoding DAP12 or the gene encoding the associated cell surface receptor TREM-2 (refs. 18, 19) . NHD is characterized by brain demyelination and gliosis, which engender presenile dementia, as well as by polycystic osteodysplasia, which causes spontaneous fractures. DAP12 is expressed in microglia and osteoclasts, which suggests that NHD may result from impaired function and/or differentiation of these cells.
Three independent lines of DAP12-deficient mice have been generated, and studies of these mice have collectively confirmed the function of DAP12 in mononuclear phagocytes. DAP12-deficient mice develop osteopetrosis [20] [21] [22] because DAP12-deficient osteoclast precursors differentiate poorly into osteoclasts [20] [21] [22] [23] [24] , mainly because of impaired integrin signaling 25 . However, whether microglia are defective in DAP12-deficient mice is unclear. One study of mice expressing a mutant DAP12 lacking its ITAM reported delayed postnatal differentiation and migration of microglia into the CNS, whereas microglia in adult mice seemed normal 22 . In contrast, a study of DAP12-deficient mice reported no defect in microglia but reported abnormal development of oligodendrocytes, hypomyelination and synaptic degeneration 20 . In addition to producing defects in osteoclasts and microglia, DAP12 deficiency also augments cytokine secretion and Erk activation in macrophages in response to microbial stimuli 26 . However, a mechanism involving DAP12 that would account for the CNS defect and the skewed macrophage activation has yet to be defined.
Here we demonstrate that DAP12-deficient mononuclear phagocytes were less responsive to M-CSF in vitro; as a result, DAP12-deficient phagocytic monocytes had diminished proliferation and survival. In vivo, DAP12 deficiency resulted in profoundly fewer microglial cells in certain areas of the CNS of older mice, as well as less regeneration of myeloid cells after bone marrow transplantation. Mechanistically, we show that CSF1-R signaling involved the stabilization, tyrosine phosphorylation and nuclear translocation of b-catenin (A000506), which are essential for the subsequent activation of genes that facilitate cell division. Notably, DAP12 was essential for optimal phosphorylation and nuclear accumulation of b-catenin. Moreover, this process involved the tyrosine kinase Pyk2 (A001952; also called CADTK). Skewed M-CSF signaling and defective proliferation and survival of DAP12-deficient mononuclear phagocytes may therefore contribute to the pathology of patients with NHD.
RESULTS

Impaired growth of DAP12-deficient macrophages
During routine culture of wild-type and DAP12-deficient bone marrow cells with M-CSF to generate bone marrow-derived macrophages (BMDMs), we noted a deficit in the yield of DAP12-deficient macrophages compared with that of wild-type macrophages. To quantify this deficiency, we cultured DAP12-deficient and wildtype bone marrow cells for 10 d with M-CSF and counted all viable cells at various time points. In wild-type cultures, the number of BMDMs increased until day 7 of culture and decreased at day 10 ( Fig. 1a) . As macrophages rapidly degrade M-CSF, this decrease may have reflected consumption of M-CSF in the cultures, which results in growth arrest and apoptosis. Notably, at day 7 and day 10, DAP12-deficient cultures had significantly fewer cells than did wild-type cultures (Fig. 1a) .
That decrease could have been due to less proliferation or more cell death. To assess the contribution of each of these mechanisms, we collected cells at days 5, 7 and 10 of culture and analyzed cell cycle and cell death by measuring DNA content with propidium iodide. In contrast to wild-type BMDMs, DAP12-deficient BMDMs showed arrest of cells in G1 at days 5 and 7, and their cultures contained slightly more hypodiploid cells that corresponded to apoptotic cells (Fig. 1b) . These data suggest that DAP12-deficient cells divide less efficiently than do wild-type cells in response to M-CSF at these time points. In addition, we found many more hypodiploid cells in DAP12-deficient cultures but not wild-type cultures at day 10 ( Fig. 1b) . Thus, DAP12 may be required for both M-CSF-dependent macrophage proliferation and survival, and its contribution to each process may vary at different culture stages.
DAP12 is needed for M-CSF-induced proliferation
To directly measure the effect of DAP12 deficiency on M-CSF-induced proliferation, we stimulated wild-type and DAP12-deficient BMDMs at day 5 of culture with two different concentrations of M-CSF and analyzed the cell cycle by propidium iodide staining. The percentage of DAP12-deficient BMDMs in either S or G2 phase was lower and the percentage in G1 phase was higher relative to wild-type BMDMs at each M-CSF concentration (Fig. 2a) . Retroviral transduction of DAP12 into DAP12-deficient BMDMs reconstituted a cell cycle profile similar to that of wild-type cells (Fig. 2b) , which directly linked DAP12 deficiency to less proliferation. We also quantified the proliferation of wild-type and DAP12-deficient BMDMs by analyzing incorporation of the thymidine analog BrdU by flow cytometry. Only 14.6% ± 1.8% of DAP12-deficient cells incorporated BrdU, compared with 44.6% ± 2.9% of wild-type cells (Fig. 2c) , which further demonstrated a defect in the proliferative response to M-CSF in DAP12-deficient cells. To confirm the defect in cell cycling, we measured expression of mRNA transcripts encoding cell cycleregulatory proteins in BMDMs. Compared with wild-type cells, DAP12-deficient cells expressed less c-Myb mRNA at day 5 and less c-Myc, cyclin D1 and cyclin D2 mRNA at days 5 and 7 of culture (Fig. 2d) . To rule out the possibility that DAP12-deficient BMDMs proliferate poorly in response to M-CSF because of a general defect in macrophage differentiation, we transduced wild-type BMDMs with retrovirus encoding a dominant negative form of DAP12 (DAP12-DN) that lacks a functional ITAM. Expression of DAP12-DN caused considerable cell cycle arrest in G1 and inhibited BrdU incorporation (Fig. 2e,f) . Overall, these data confirm the involvement of DAP12 in M-CSF-driven proliferation.
DAP12 in M-CSF-induced macrophage survival
To assess the function of DAP12 in macrophage survival, we deprived BMDMs of M-CSF for 24 h and measured apoptosis by propidium iodide staining. Wild-type cells were more resistant to apoptosis than were DAP12-deficient BMDMs (Fig. 3a,b) . Retroviral transduction of DAP12 into DAP12-deficient BMDMs resulted in much less apoptosis (Fig. 3c) , which connected DAP12 deficiency with lower survival. BMDM cultures contain endogenous M-CSF, which is produced by contaminating fibroblast-like stromal cells. Therefore, to precisely quantify the difference in the M-CSF-induced survival of wild-type and DAP12-deficient BMDMs, we generated pure myeloid precursor cultures free of contaminating fibroblast-like stromal cells 27 . We seeded these precursors for 4 d in equal numbers in various amounts of M-CSF. Pure cultures of wild-type macrophages required exogenous M-CSF for survival, and there was a dose-response relationship between the number of cells that remained after 4 d and the dose of M-CSF (Fig. 3d) . In contrast, DAP12-deficient cultures had fewer cells than wild-type cultures did at all M-CSF concentrations.
To confirm that DAP12-deficient macrophages die by apoptosis, we cultured BMDMs for 16 h in the presence or absence of M-CSF, then lysed the cells and assessed the presence of active caspase-3 by immunoblot analysis. We detected no active caspase-3 in lysates of wild-type cells grown with or without M-CSF. In contrast, DAP12-deficient cells had large amounts of active caspase-3 after withdrawal of M-CSF (Fig. 3e) . Together these experiments demonstrate a quantitative defect in M-CSF-induced survival of DAP12-deficient macrophages.
To determine whether wild-type cells produce an extrinsic factor required for the survival of BMDMs, we assessed the survival of wildtype and DAP12-deficient BMDMs cultured together. We mixed bone marrow from DAP12-sufficient, GFP-expressing transgenic mice at a ratio of 1:1 with bone marrow from wild-type or DAP12-deficient mice and cultured the cells together for 5 d in the presence of M-CSF to generate BMDMs. We continued cultures for 2 additional days in the absence of M-CSF and, on day 7, determined the ratio of GFP + BMDMs to GFP -BMDMs. There was a slight but reproducible predominance of wild-type (GFP -) cells over GFP + cells (58% versus 42%) in the cocultures of wild-type and GFP + cells (Fig. 3f) , which suggested that wild-type cells had a slight survival or proliferation advantage. However, in cocultures of DAP12-deficient cells and GFP + BMDMs, there was selective loss of almost half of the DAP12-deficient (GFP -) cells, such that 71% of the cells remaining in culture were GFP + .
We did similar studies focusing on the related signaling adaptors DAP10 and FcRg 17 . However, culture of bone marrow from DAP10-deficient or FcRg-deficient mice together with GFP + bone marrow suggested that neither DAP10 nor FcRg influences macrophage proliferation or survival (Fig. 3f) . These data collectively indicate that the defect in the survival of DAP12-deficient macrophages is specific to DAP12 and, as survival could not be restored by a soluble or cell surface factor present in wild-type cultures, it is cell intrinsic.
Little influence of DAP12 on BMDM differentiation As macrophage proliferation and differentiation are coordinately regulated 28 , we sought to determine whether DAP12 deficiency, although it diminished proliferation, accelerated the differentiation of bone marrow cells into mature macrophages in vitro. Both DAP12-deficient and wild-type BMDMs expressed typical macrophage markers, although DAP12-deficient macrophages had lower expression of CD11b, major histocompatibility complex class II, the receptors CD36 and F4/80, and apolipoprotein E, whereas CSF-1R expression was unchanged ( Supplementary Fig. 1 online) . Collectively, these observations indicate that lack of DAP12 does not accelerate the M-CSF-induced differentiation of mature macrophages.
Microglial defects in DAP12-deficient mice Given the considerable defects in the proliferation and survival of DAP12-deficient macrophages in response to M-CSF in vitro, we sought to determine whether any abnormality would be manifested in vivo. We compared microglia in the brains and spinal cords of wildtype and DAP12-deficient mice by staining for the microglial marker Iba-1 in young mice (4 weeks old) and older mice (10 months old). We found significantly fewer microglia in the basal ganglia (10.6 ± 3.9 cells per mm 2 versus 61.2 ± 8.8 cells per mm 2 ; P o 0.001) and the spinal cord (6.2 ± 4.5 cells per mm 2 versus 37.3 ± 5.8 cells per mm 2 ; P o 0.001; mean ± s.d.) in older DAP12-deficient mice than in wildtype control mice (Fig. 4) . Furthermore, at high magnification, we found extensive cytoplasmic fragmentation (cytorrhexis) and nuclear condensation characteristic of microglial degeneration and apoptotic cell death in the DAP12-deficient mice (Fig. 4) . Young wild-type and DAP12-deficient mice had similar numbers of microglia (data not shown). Additionally, we found no detectable differences between wild-type and DAP12-deficient mice in myelopoiesis, circulating myeloid cells or peripheral macrophages in the spleen and liver (Supplementary Fig. 2 and Supplementary Table 1 online) . On the basis of these observations, we conclude that DAP12 is required for the long-term preservation of a specific microglia subset.
DAP12 in mononuclear phagocyte repopulation
To compare the generation of DAP12-deficient versus wild-type macrophages in vivo, we mixed bone marrow from DAP12-sufficient transgenic mice expressing GFP at a ratio of 1:1 with bone marrow from DAP12-deficient (GFP -) or wild-type (GFP -) mice (Fig. 5a) . We then engrafted the mixed bone marrow into lethally irradiated wildtype hosts, which resulted in mice in which the GFP -bone marrow was either wild-type in origin (wild-type-GFP chimeras) or DAP12-deficient in origin (DAP12-KO-GFP chimeras). We maintained these mice for up to 36 weeks and evaluated bone marrow chimerism by flow cytometry at 12, 19 and 36 weeks after engraftment.
At 12 weeks, the GFP + bone marrow/GFP -bone marrow ratio in the chimeric mice closely reflected the input ratio (Fig. 5b) . At 19 weeks, the proportion of GFP + cells decreased (relative to input) in the wild-type-GFP chimeras, which suggested that the wild-type GFP -cells were more robust than the GFP + cells. In contrast, the proportion of GFP + cells remained stable in the DAP12-KO-GFP chimeras, which indicated that the DAP12-deficient cells competed less well than did wild-type cells in vivo, much as they did in vitro. At 36 weeks, there was a preponderance of GFP -cells in all chimeras. However, the ratio of GFP -cells to GFP + cells was much greater in the wild-type-GFP chimeras than in the DAP12-KO-GFP chimeras (Fig. 5b) . There was no deficit in the total number of nucleated cells in the bone marrow (wild-type-GFP and DAP12-KO-GFP chimeras had 2.9 Â 10 7 and 2.6 Â 10 7 nucleated cells per femur, respectively, at 36 weeks, consistent with results obtained with unmanipulated mice (data not shown)). These findings indicate that changes in the GFP + cell/GFP -cell ratio reflected replacement of GFP + cells by GFP -cells. Collectively, these data demonstrate that DAP12-deficient bone marrow cells repopulate the bone marrow of irradiated recipient mice less efficiently than do wild-type cells.
We also assessed peripheral cell populations in the chimeric mice at 36 weeks. We examined blood polymorphonuclear cells (CD115 -Gr-1 hi ), blood monocytes (CD115 + Gr-1 lo-int ), peritoneal B cells (CD19 + ) and peritoneal macrophages (F4/80 + ; Fig. 5c ). The GFP -/GFP + ratio of polymorphonuclear cells was about 2:1 in the wild-type-GFP and DAP12-KO-GFP chimeras (Fig. 5d) . In contrast, the GFP -/GFP + ratio of monocytes in the wild-type-GFP chimeras was greater than that in the DAP12-KO-GFP chimeras (3:1 versus 2:1), similar to that in the bone marrow (Fig. 5d) . Those findings were consistent with defective proliferation and/or survival of DAP12-deficient monocytes and/or macrophages. In the peritoneum, we found no difference in the GFP -/ GFP + ratio of B cells in wild-type-GFP and DAP12-KO-GFP chimeras (about 2:1; Fig. 5d ). In contrast, there were more peritoneal GFPmacrophages than GFP + macrophages in the wild-type-GFP chimeras (85% versus 15%) than in DAP12-KO-GFP chimeras (75% versus 25%). These results collectively support the idea that DAP12 is involved in promoting the proliferation and survival of monocytes and/or macrophages in vivo. 
DAP12 deficiency skews M-CSF-induced signaling The inefficient M-CSF-induced proliferation and survival of DAP12-deficient cells indicated that DAP12 is involved in M-CSF signaling.
Studies have demonstrated that CSF-1R induces proliferation by activating Erk 29 . Thus, we sought to determine whether CSF-1R requires DAP12 for the activation of Erk and other mitogen-activated protein kinases (MAPKs). We stimulated wild-type and DAP12-deficient BMDMs with M-CSF for various periods of time and analyzed 'downstream' signaling intermediates by immunoblot. M-CSF induced prompt phosphorylation of the MAPKs Erk, p38 and Jnk and the 'downstream' target p90rsk in wild-type cells (Fig. 6a and data not shown). DAP12 deficiency did not result in less MAPK activation; in fact, we found slightly but reproducibly greater phosphorylation of Erk, p38 and p90rsk in DAP12-deficient cells (Fig. 6a) , whereas Jnk phosphorylation was unchanged (data not shown). Thus, the impaired M-CSF-induced proliferation of DAP12-deficient macrophages cannot be accounted for by less activation of Erk. Notably, it has been reported that M-CSF induces transcriptional activation of MAPK phosphatase 1 (MKP-1) 29 , which dephosphorylates p38 and Erk 30 . As DAP12-deficient macrophages were less responsive to M-CSF, we assessed whether they had lower expression of MKP-1 and found that this was indeed the case (Fig. 6) . This lower MKP-1 expression provides a likely explanation for the paradoxically greater phosphorylation of Erk and p38 in DAP12-deficient cells. Although it has been shown that CSF-1R induces macrophage survival by activating PI(3)K-Akt 29 , we found no difference in M-CSF-induced phosphorylation of Akt in DAP12-deficient and wild-type cells (Fig. 6a) . We conclude that DAP12 controls CSF-1R-induced proliferation and survival through a MAPK-independent pathway.
M-CSF activates b-catenin via DAP12
Among other pathways known to promote cell growth and inhibit apoptosis, the b-catenin pathway was a likely candidate because b-catenin, after nuclear translocation, acts a coactivator of the transcription factors TCF and LEF to induce the transcription of genes involved in the cell cycle (such as those encoding cyclin D1 (refs. 31,32) and c-Myc 33 ), which were expressed differently in wildtype and DAP12-deficient BMDMs. Activation of the b-catenin pathway depends on the stabilization of b-catenin and its nuclear translocation 34 . Stability of b-catenin is negatively regulated by GSK3b, which phosphorylates serine and threoinine residues of b-catenin and thereby induces its subsequent proteasome-mediated degradation 34 . Nuclear localization is positively regulated by tyrosine phosphorylation 35, 36 . Immunoblot analysis of lysates of BMDMs showed that M-CSF increased the b-catenin in wild-type cells (Fig. 7a) , which indicates involvement of M-CSF in regulating b-catenin stability. The expression of b-catenin also increased in M-CSF-stimulated DAP12-deficient cells, although to a lesser extent; this finding suggests that DAP12 may influence b-catenin stabilization.
We next sought to determine how M-CSF and DAP12 mediate the activation of b-catenin. M-CSF induced phosphorylation of GSK3b at the serine at position 9 (Ser9) in wild-type BMDMs (Fig. 7b) . As phosphorylation of Ser9 inhibits GSK3b function, this may explain at least in part the M-CSF-induced stability of b-catenin. Phosphorylation of GSK3b at Ser9 was DAP12 independent, as it was similar in M-CSF-stimulated wild-type and DAP12-deficient BMDMs. M-CSF also induced tyrosine phosphorylation and nuclear translocation of b-catenin in wild-type BMDMs (Fig. 7c,d) . Notably, M-CSFinduced tyrosine phosphorylation and nuclear translocation of b-catenin were much lower in DAP12-deficient BMDMs (Fig. 7c,d ). After nuclear translocation, b-catenin activates 'downstream' target genes by interacting with the transcription factors LEF and TCF 34 . To confirm that M-CSF induces the nuclear translocation of b-catenin and activation of LEF and TCF, we transduced wild-type and DAP12-deficient BMDMs with a luciferase reporter driven by three LEF-TCF sites. M-CSF stimulation activated the reporter in wild-type cells but not in DAP12-deficient cells (Fig. 7e) . Additionally, there was much less nuclear accumulation of b-catenin in wild-type BMDMs transduced with DAP12-DN (Fig. 7f) . Collectively, these experiments demonstrate that M-CSF activates the b-catenin pathway and that DAP12 is required for M-CSF-induced tyrosine phosphorylation and nuclear translocation of b-catenin.
To confirm the involvement of b-catenin activation in the M-CSFinduced proliferation of BMDMs, we treated wild-type and DAP12-deficient BMDMs with the GSK3b-specific inhibitor SB216763 and measured BMDM proliferation as BrdU incorporation. Inhibition of GSK3b promoted M-CSF-induced the proliferation of BMDMs and restored the proliferation of DAP12-deficient BMDMs to that of wild-type BMDMs (Fig. 7g) . We conclude that b-catenin activation is crucial for the M-CSF-DAP12 pathway that stimulates BMDM proliferation.
Pyk2 links DAP12 to b-catenin tyrosine phosphorylation Next we sought to identify molecular mediators that facilitate the DAP12-mediated tyrosine phosphorylation of b-catenin. One plausible candidate was the tyrosine kinase Pyk2. DAP12 activates Pyk2, which results in enhanced signaling of certain cytokines 37, 38 , and Pyk2 mediates the phosphorylation of b-catenin 39 . To directly address whether DAP12 induces the phosphorylation of b-catenin via Pyk2, we stimulated wild-type and DAP12-deficient BMDMs with M-CSF and assessed Pyk2 phosphorylation as a measure of activation. M-CSF induced Pyk2 phosphorylation much more robustly in wild-type BMDMs than in DAP12-deficient BMDMs, and this phosphorylation was inhibited in wild-type BMDMs expressing DAP12-DN (Fig. 8a,b) . Moreover, transduction of wild-type BMDMs with DAP12-DN or a dominant negative form of Pyk2 (CADTK-related non-kinase (CRNK)) 40 prevented tyrosine phosphorylation of b-catenin by M-CSF (Fig. 8c) . Finally, Pyk2 precipitated together with b-catenin from wild-type M-CSF-stimulated BMDMs but not from DAP12-deficient M-CSF-stimulated BMDMs (Fig. 8d) . To confirm the involvement of Pyk2-mediated b-catenin activation in M-CSF-DAP12-induced proliferation of BMDMs, we showed that two pharmacological inhibitors of Pyk2 inhibited the M-CSF-induced proliferation and cell cycle progression of BMDMs, as assessed by BrdU and propidium iodide assays (Fig. 8e) . Additionally, transduction of wild-type BMDMs with CRNK resulted in less cell cycle progression and proliferation induced by M-CSF (Fig. 8f,g ). M-CSF induces activation of the tyrosine kinase Syk through DAP12 in osteoclasts 41 . Therefore, we also evaluated the involvement of Syk in M-CSF-induced b-catenin activation. M-CSF induced DAP12-dependent tyrosine phosphorylation of Syk in BMDMs ( Supplementary Fig. 3a online) , but Syk was not present in b-catenin immunoprecipitates (data not shown), which suggested that Syk has no direct function in DAP12-induced tyrosine phosphorylation of b-catenin. Because a pharmacological inhibitor of Syk inhibited the M-CSF-induced proliferation of BMDMs ( Supplementary Fig. 3b) , it is likely that Syk acts as an 'upstream' activator of the Pyk2-bcatenin pathway.
M-CSF activates b-catenin independently of cell adhesion
It is well established that stimulation of macrophages with M-CSF induces remodeling of the actin cytoskeleton and formation of adhesion structures reflective of integrin activation 42 . Moreover, integrin signaling in macrophages involves DAP12 and Syk 43 and mediates a tonic Pyk2 activation that regulates responsiveness to interferon-a 37 . Thus, M-CSF could trigger the DAP12-Pyk2-bcatenin signaling pathway by promoting 'inside-out' integrin activation. To explore that possibility, we first determined whether DAP12-deficient BMDMs have adhesion defects. In the absence of M-CSF, wild-type and DAP12-deficient BMDMs attached equally well to fibronectin under both static and continuous flow conditions ( Supplementary Fig. 4 online) . However, stimulation of BMDMs with M-CSF did not further increase adhesion in these assays, probably because of the considerable basal ability of BMDMs to adhere to fibronectin. Therefore, we investigated M-CSF-induced cytoskeleton reorganization and formation of focal complexes in adherent BMDMs as an indication of macrophage adhesion and integrin activation. After 12 h of M-CSF withdrawal, stimulation of wild-type BMDMs with M-CSF resulted in considerable actin reorganization and cell spreading, with the formation of membrane ruffles, lamellipodia and filopodia ( Supplementary Fig. 5 online) . We found nearly identical changes in DAP12-deficient BMDMs. Moreover, staining of wild-type and DAP12-deficient BMDMs with antibody to vinculin (anti-vinculin) showed similar increases in the number and clustering of focal complexes ( Supplementary Fig. 6a online) . M-CSF-induced redistribution of the integrin CD11b was also equivalent in wild-type and DAP12-deficient BMDMs (Supplementary Fig. 6b ). Thus, M-CSFinduced adhesion and rearrangement of the actin cytoskeleton are not noticeably affected by lack of DAP12, at least in BMDMs.
If the M-CSF-DAP12 pathway to b-catenin activation is independent of integrin signaling, it should occur also when BMDMs are in suspension. M-CSF stimulation of wild-type and DAP12-deficient BMDMs in suspension neither increased their ability to bind a soluble ICAM-1-Fc fusion protein nor enhanced clustering of the integrins VLA-4, CD11b and LFA-1 on the cell surface (data not shown), which indicates that M-CSF does not activate integrins on BMDMs in suspension. However, M-CSF was equally effective in inducing Pyk2 phosphorylation and increasing b-catenin in wild-type BMDMs whether cells were in suspension or attached to plates ( Supplementary Fig. 7 online) . These results indicate that 
DISCUSSION
Our report has demonstrated that DAP12 is essential for CSF-1R signaling, specifically for enhancing the proliferation and survival of macrophages in response to M-CSF. Mechanistically, DAP12 facilitated Pyk2-mediated tyrosine phosphorylation and subsequent nuclear translocation of b-catenin. DAP12-deficient macrophages proliferated poorly in response to M-CSF and did not survive in suboptimal amounts of M-CSF in vitro. These defects were cell intrinsic. Notably, the impaired responses of DAP12-deficient macrophages to M-CSF in vitro had a correlate in vivo. Relatively few microglia were present in the basal ganglia and spinal cords of 10-month-old DAP12-deficient mice, and those that remained had an apoptotic phenotype. In addition, DAP12-deficient myeloid precursors reconstituted the monocyte and macrophage compartment less effectively than did precursors from wild-type mice after bone marrow transplantation. So far, analysis of DAP12-deficient mouse models has yielded ambiguous results regarding the function of DAP12 in microglia 20, 22 . Our results have conclusively demonstrated lower numbers and diminished survival of microglia in particular areas of 10-month-old DAP12-deficient CNS; these defects may stem from less responsiveness to M-CSF. Our examination of the basal ganglia and spinal cords of older mice may have made our analysis more sensitive than another published study of this line of DAP12-deficient mice 20 .
Notably, mononuclear phagocytes do not uniformly rely on M-CSF for survival 13 . Although osteoclasts and spleen macrophages are entirely M-CSF dependent, microglia require M-CSF only in specific areas of the CNS [14] [15] [16] . This may explain why DAP12 deficiency exclusively affected microglia in restricted locations in the CNS. Because microglia are critical for local defense and trophism, confined impairment of microglia in a discrete location may predispose the CNS to distinct pathological defects such as those that occur in NHD. It is possible that DAP12 is involved in M-CSF-induced proliferation and survival of mononuclear phagocytes other than microglia, but a continuous supply of M-CSF may compensate for a lack of DAP12. Future studies should address the contribution DAP12 in conditions in which M-CSF is limiting or rapidly consumed.
In addition to resulting in lower proliferation and survival of mononuclear phagocytes, DAP12 deficiency augmented M-CSFinduced MAPK activation. As M-CSF induces MKP-1 expression 29 , impaired responses to M-CSF in DAP12-deficient macrophages may result in lower expression of MKP-1 and consequently more MAPK phosphorylation. Lower MKP-1 expression may also explain the enhanced Erk activation and cytokine responses to Toll-like receptor agonists reported before in DAP12-deficient BMDMs 26 .
Notably, we found that CSF-1R activated the b-catenin pathway, which is known to control cell proliferation and survival in other cell types 34 . Activation of the b-catenin pathway depends on stabilization of b-catenin and its nuclear translocation. We found that M-CSF acted on both processes. M-CSF induced phosphorylation of GSK3b at Ser9, which diminished GSK3b kinase activity and therefore promoted b-catenin stability. Additionally, M-CSF induced tyrosine phosphorylation and subsequent nuclear translocation of b-catenin. Although DAP12 had no effect on GSK3b phosphorylation, it was absolutely required for the tyrosine phosphorylation and nuclear accumulation of b-catenin. The diminished nuclear translocation of b-catenin in DAP12-deficient BMDMs provides a likely explanation for the lower abundance of cyclin D1 and c-Myc mRNA transcripts in these cells than in wild-type BMDMs. Studies have demonstrated that b-catenin is important for the self-renewal and maintenance of hematopoietic stem cells and myeloid progenitor cell pools 44 . Our results have extended those studies, showing that b-catenin is important not only at the stem cell stage but also at later stages of macrophage population expansion and differentiation, when DAP12 and its associated receptors are expressed. This was particularly evident in the mixed-bone marrow chimera experiments, in which DAP12-deficient bone marrow repopulated irradiated hosts but generated fewer mature monocytes and macrophages than did wild-type bone marrow. Finally, we have identified Pyk2 as the tyrosine kinase that links DAP12 to tyrosine phosphorylation of b-catenin. Published studies have described Pyk2 as a 'downstream' signaling intermediate of DAP12 (refs. 37,38) , as well as an effector of b-catenin phosphorylation 39 . Consistent with both observations, we found that M-CSF induced Pyk2 activation and its association with b-catenin in a DAP12-dependent way. The signaling pathway that connects DAP12 and Pyk2 remains to be elucidated. Although M-CSF activates cell adhesion and DAP12 is known to be a mediator of integrin signaling 43 , our data indicate that the M-CSF activation of the DAP12-Pyk2-b-catenin pathway is adhesion independent. Thus, this pathway seems to be distinct from the cell attachment-DAP12-Pyk2 pathway that mediates tonic regulation of interferon-a and interleukin 10 signaling 37 . A published study 41 and our own data suggest that M-CSF-DAP12 may act through Syk and possibly other kinases that have been linked to macrophage survival and osteoclast function, such as TEC 45, 46 . In conclusion, our identification of a link among M-CSF, the DAP12 ITAM and b-catenin has demonstrated a signaling network that regulates the proliferation and survival of myeloid cells.
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